fbpx
clinical_research_graphic_png

New EU-funded project REBECCA to improve post-treatment in breast cancer

EBECCA, REsearch on BrEast Cancer induced chronic conditions supported by Causal Analysis of multi-source data, is a new project funded under the European Union’s Horizon 2020 research and innovation programme. REBECCA aims to tap into the potential of Real-World Data to support clinical research and to improve existing clinical workflows.
REBECCA will combine clinical data with data describing patients’ real-life behavior including their physical activity, eating habits and sleep as well as information related to their online interaction. These new forms of Real-World Data will become available thanks to the analysis of sensor and log data collected via mobile and wearable devices. Novel functional and emotional indices will be produced for each individual and their ability to characterise patient status and quality of life will be examined. REBECCA promotes the use of these indices as a tool for monitoring and optimising patient care and also as complementary outcomes during clinical research.

REBECCA 360o platform, a combination of minimally obtrusive, non-stigmatising mobile applications will be offered to breast cancer survivors as a means of supporting their everyday life and enhancing their interaction with health experts. The same system will be able to collect details of patients functional and emotional status during their participation in clinical research campaigns.

The project and more precisely the REBECCA 360o platform brings together clinical data and data obtained from technological universities, industry leaders, public health experts, and patient associations from 7 European countries to work together to shape future guidelines and practices for post-cancer treatment.

Data collected by REBECCA will be processed by innovative Causal Analysis models focusing on the complex array of chronic comorbidities developed during breast cancer recovery, overcoming many of the limitations of traditional Randomised Controlled Trials.

Εuropean Health Management Association (EHMA) is a partner in a new EU-funded project, REBECCA, which aims to improve post-treatment in breast cancer. REBECCA, stands for REsearch on BrEast Cancer induced chronic conditions supported by Causal Analysis of multi-source data, will tap into the potential of Real-World Data to support clinical research and to improve existing clinical workflows.

REBECCA kicked off in April 2021 and is set to last until March 2025, with a budget of 5.2 million EUR. It brings together 12 partners from 7 European countries, and is led by the Aristotle University of Thessaloniki.

Share this post

Share on facebook
Share on linkedin
Share on twitter
Share on print
Share on email